The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor Relations to their team. The successful candidate has a foundation of finance and investor relations experience to draw from in developing and implementing investor relations strategy and communications. This role will support the executive leadership team in helping to build relationships with a range of investors and analysts. Ionis is a financially strong company with a robust pipeline and this individual will have the opportunity to have a meaningful impact as the company strives to discover and develop antisense drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological diseases and cancer. The Chase Group appreciates and values our continued partnership with Ionis. We are proud to connect this patient focused company with high caliber talent that shares their passion and drive to help the sick people that depend on them.
The Chase Group Successfully Secures Vice President, Head of Medical Development for Checkmate Pharmaceuticals
Building on a 14+ year relationship with Chase, the Chief Medical Officer of Checkmate Pharmaceuticals retained The Chase Group to identify a critical hire for…
Search Executed by The Chase Group, Inc. Results in Successful Appointment of Dr. Christophe Hotermans as SVP, Global Medical Affairs for Akcea Therapeutics
The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President,…-
Appointment of William Andrews, M.D. as Chief Medical Officer at Akcea Therapeutics Successfully Completed by The Chase Group
The Chase Group, known for relationship building with proven success in life sciences executive search, was retained by Akcea Therapeutics, to identify and secure a… 
Biologics Consulting Leadership Team Grows Through Partnership with The Chase Group
Through focused collaboration with The Chase Group, Biologics Consulting has entered a season of growth by successfully placing, in a newly created position, a Director,…
The Chase Group Secures New Leader for Informatics & Computational Biology at the Allen Institute for Immunology
Following an extensive search of industry and academic professionals by The Chase Group, the Allen Institute for Immunology welcomes a new Director, Informatics & Computational…-
The Chase Group Successfully Completes the Appointment of Carla Poulson as Senior Vice President/Chief Human Resources Officer at Akcea Therapeutics
After a comprehensive executive search that was filled in less than two months, The Chase Group is pleased to announce the placement of Carla Poulson…